Clinical Trial Update: A Study of ISIS 416858 Administered Subcutaneously to Participants With End-Stage Renal Disease (ESRD) on Hemodialysis [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating ISIS 416858 given subcutaneously to participants with end-stage renal disease on hemodialysis has been completed with results …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• End-stage Renal Disease
• Kidney Disease

Drugs mentioned

• ISIS 416858

Snippet

Sponsor: Ionis Pharmaceuticals, Inc. | Conditions: End-stage Renal Disease (ESRD) | Phase 2 | Status: COMPLETED | Results posted: 2023-01-20